Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | SCN9A | Q15858 | 5/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.44 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.41 |
| ▸ | CCR6 | P51684 | 3/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | BCR | P11274 | 1/20 | 0.40 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
| ▸ | IDH2 | P48735 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1269926 | 0.91 | ALDH1A1 (0.46) | GAASCN9ASCN5ACCR6PIK3C3 | |
| SCHEMBL1268492 | 0.88 | GAA (0.45) | GAAPKMSCN9AEPHX2PIK3C3 | |
| SCHEMBL1268685 | 0.86 | GAA (0.43) | GAAPKMSCN9AEPHX2SCN5A | |
| SCHEMBL1268674 | 0.85 | GAA (0.42) | GAAPKMSCN9AEPHX2PIK3C3 | |
| SCHEMBL1269603 | 0.85 | GAA (0.45) | GAAPKMSCN9AEPHX2CCR6 | |
| SCHEMBL1268669 | 0.84 | GAA (0.45) | GAAPKMSCN9AEPHX2MAPT | |
| SCHEMBL1269770 | 0.82 | GAA (0.42) | GAAPKMSCN9AEPHX2SCN5A | |
| SCHEMBL1269704 | 0.82 | GAA (0.46) | GAAPKMSCN9AEPHX2ABL1 | |
| SCHEMBL12900226 | 0.81 | GAA (0.41) | GAAPKMSCN9AEPHX2MAPT | |
| SCHEMBL1269489 | 0.81 | GAA (0.43) | GAAPKMSCN9AEPHX2SCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7893077-B2 | Bisaryl-sulfonamides | AMGEN INC. (US) | 2011-02-22 | — | — | US | disclosed |
| US-7893077-B2 | Bisaryl-sulfonamides | AMGEN INC. (US) | 2011-02-22 | — | — | US | disclosed |
| US-20090221584-A1 | Bisaryl-sulfonamides | AMGEN INC. | 2009-09-03 | — | — | US | disclosed |
| US-20090221584-A1 | Bisaryl-sulfonamides | AMGEN INC. | 2009-09-03 | — | — | US | disclosed |
| US-7544702-B2 | Bisaryl-sulfonamides | AMGEN INC. (US) | 2009-06-09 | — | — | US | disclosed |
| US-7544702-B2 | Bisaryl-sulfonamides | AMGEN INC. (US) | 2009-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221584-A1 | Bisaryl-sulfonamides | PPARD, PPARA, PPARG | GAA 1704/4885PKM 3049/4885SCN9A 4080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.